A new clinical study aims to evaluate the efficacy of high-power laser devices in managing symptoms of meralgia paresthetica. Medical and regulatory professionals across clinical, quality, and research spheres may monitor this development, which focuses on exploring advanced therapeutic interventions.
What changed?
On January 10, 2026, details about a clinical trial for treating meralgia paresthetica with high-power laser therapy were made available. This trial, sponsored by Uşak University and Balikesir University, represents a focused inquiry into whether innovative device technologies can relieve nerve-related pain. The trial is in its pre-recruitment phase and will compare high-power lasers, sham lasers, and standard conservative care.
Study interventions and objectives
This trial investigates three intervention categories:
- A high-power laser device for targeted therapy.
- A sham laser to establish a valid control for assessing the primary device’s efficacy.
- Standard conservative care offering a conventional approach as an additional benchmark.
Meralgia paresthetica is characterized by numbness, tingling, or pain in the outer thigh due to compression of the lateral femoral cutaneous nerve. While standard treatments such as physical therapy and medication exist, this study evaluates whether advanced laser technology offers superior long-term symptom relief. Researchers will focus on device performance, safety, and patient outcomes.
Sponsor information and recruitment status
Uşak University and Balikesir University are the academic collaborators leading this inquiry. As of now, participant recruitment has not started. Patients diagnosed with meralgia paresthetica and others involved in pain management research may follow updates to assess whether the trial aligns with their interests or clinical needs.
Frequently asked questions
- Who is eligible to participate in the study?
Currently, eligibility criteria have not been specified, but updates will likely be available closer to the recruitment phase. - What is the study’s primary focus?
This trial will assess the efficacy, safety, and therapeutic potential of high-power laser technology in managing meralgia paresthetica symptoms. - When will recruitment begin?
The trial is not yet recruiting as of early 2026. Updates will be posted on the official ClinicalTrials.gov page. - Where can I find detailed trial data?
Comprehensive information is listed under ClinicalTrials.gov with reference ID NCT07328360.
Key takeaways
The upcoming study represents a notable step forward in generating high-quality clinical evidence for medical devices targeting nerve dysfunctions like meralgia paresthetica. Stakeholders in clinical practice, regulatory bodies, and device manufacturing could find the study outcomes impactful when evaluating novel treatment pathways. Professionals are encouraged to monitor recruitment and trial updates for further development.
Disclaimer
This article is intended for informational purposes only. It does not constitute legal or clinical advice. Please consult relevant professionals for detailed guidance or decision-making related to medical device regulations or treatments.
Full details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07328360?term=medical+device